Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Note (Details)

Stockholders' Equity, Note (Details) (USD $)	3 Months Ended		12 Months Ended		3 Months Ended		1 Months Ended	3 Months Ended			3 Months Ended
Stockholders' Equity, Note (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014 Series B Preferred Stock	Mar. 31, 2014 Series C Preferred Stock	Jan. 31, 2014 Series D Preferred Stock	Mar. 31, 2014 Series D Preferred Stock	Oct. 31, 2013 Series D Preferred Stock	Jan. 26, 2012 Treasury Stock Transaction	Mar. 31, 2014 2011 Equity Incentive Plan, Employees	Mar. 31, 2014 2011 Equity Incentive Plan, Directors	Mar. 31, 2014 2011 Equity Incentive Plan, Employee	Mar. 31, 2014 Series D Unit offering	Mar. 31, 2014 Non-public offering of notes and warrants	Mar. 31, 2014 Non-public offering of notes and warrants(2)
Common stock authorized	20,000,000		20,000,000
Common shares issued and outstanding	8,271,398		8,082,000
Preferred stock authorized	4,500,000		4,500,000
Preferred stock outstanding	927,915		1,005,648
Shares outstanding					101,935	45,000		780,980
Preferred shares converted to common shares					75,065	56,000
Annual dividend rate					$ 0.16	$ 0.16		$ 0.24
Accumulated dividends released					$ 26,488
Dividends accumulated					39,859	17,574
Original issue price per share					$ 2.00	$ 2.00		$ 3.00
Dividends paid						6,999		44,018
Dividends payable						17,574		45,665
Units offered (Common Stock and Warrants)									772,352
Units offered (Common Stock and Warrants), price per unit									$ 3.00
Units offered (Common Stock and Warrants), potential proceeds									2,317,056
Units offered (Common Stock and Warrants), additional over-allotment									1,000,000
Units offered (Common Stock and Warrants), potential proceeds for additional over-allotment									3,000,000
Units sold during offering							53,332
Gross proceeds from units sold in offering							159,996
Issuance costs							6,000
Beneficial conversion feature (BCF)								13,347
Common stock returned for cancellation										10,050,000
Number of options granted	184,000		410,000								94,000	40,000	50,000
Stock-based compensation expense	129,408	19,322
Unrecognized compensation expense	$ 492,371
Performance Stock options outstanding	1,440,000			1,440,000
Weighted average exercise price, performance stock options outstanding	$ 0.11			$ 0.11
Performance Stock options exercisable	40,000
Weighted average exercise price, performance stock options exercisable	$ 2.00
Number of warrants issued														26,666	283,329	50,000
Warrants outstanding	723,819		363,824
Weighted average exercise price, warrants	$ 3.00		$ 3.00
Warrants granted	359,995